Lennham Presents Topline Data From Human PK Study of D9-Caffeine vs Caffeine at ISSN 2021
View the poster presentation here.
Previous
Previous
Lennham Pharmaceuticals Expands Leading Psilocybin Patent Portfolio with Addition of New Patent Family
Next
Next